B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
HemaSphere | May 10, 2023 | Volume: 7 | Issue: S2 | Pages: 7-8
10.1097/01.hs9.0000936124.56965.24